A phase IIb study of JNJ-42847922 (MIN-202) for the treatment of patients with insomnia
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Seltorexant (Primary) ; Zolpidem
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Minerva Neurosciences
- 11 Dec 2017 Planned number of patients changed to 360.
- 06 Dec 2017 According to a Minerva Neurosciences media release, first patient has been enrolled.
- 06 Dec 2017 Status changed from planning to recruiting, according to a Minerva Neurosciences media release.